🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Sk Biopharmaceuticals Co Ltd (326030)

Seoul
Currency in KRW
112,000
-2,700(-2.35%)
Closed
326030 Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
111,700118,400
52 wk Range
72,600130,000
Bid/Ask
112,000.00 / 112,200.00
Prev. Close
114,700
Open
117,100
Day's Range
111,700-118,400
52 wk Range
72,600-130,000
Volume
551,978
Average Volume (3m)
427,067
1-Year Change
27.85%
Fair Value
Unlock
Fair Value Upside
Unlock
326030 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
110,857.00
Downside
-1.02%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Sk Biopharmaceuticals Co Ltd Company Profile

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. is a subsidiary of SK Inc.

Employees
252

Compare 326030 to Peers and Sector

Metrics to compare
326030
Peers
Sector
Relationship
P/E Ratio
259.5x−2.1x−0.7x
PEG Ratio
1.850.120.00
Price/Book
25.9x1.5x2.6x
Price / LTM Sales
18.9x2.3x3.2x
Upside (Analyst Target)
4.9%30.3%43.9%
Fair Value Upside
Unlock10.5%6.5%Unlock

FAQ

What Is the Sk Biopharma (326030) Stock Price Today?

The Sk Biopharma stock price today is 112,000.00

What Stock Exchange Does Sk Biopharma Trade On?

Sk Biopharma is listed and trades on the Seoul stock exchange.

What Is the Stock Symbol for Sk Biopharma?

The stock symbol for Sk Biopharma is "326030."

What Is the Sk Biopharma Market Cap?

As of today, Sk Biopharma market cap is 8.77T.

What is Sk Biopharma Earnings Per Share?

The Sk Biopharma EPS is 431.55.

What Is the Next Sk Biopharma Earnings Date?

Sk Biopharma will release its next earnings report on 10 Feb 2025.

From a Technical Analysis Perspective, Is 326030 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.